Laura Chico
Stock Analyst at Wedbush
(2.19)
# 2,711
Out of 4,865 analysts
222
Total ratings
34.9%
Success rate
-2.19%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Reiterates: Neutral | $121 | $126.56 | -4.39% | 17 | Jun 12, 2025 | |
| PHVS Pharvaris | Reiterates: Outperform | $27 | $16.56 | +63.04% | 6 | Jun 5, 2025 | |
| VIGL Vigil Neuroscience | Downgrades: Neutral | $13 → $8 | $7.88 | +1.52% | 11 | May 22, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Outperform | $30 | $14.10 | +112.77% | 11 | May 16, 2025 | |
| GOSS Gossamer Bio | Reiterates: Outperform | $4 | $1.24 | +222.58% | 5 | May 16, 2025 | |
| SLDB Solid Biosciences | Maintains: Outperform | $18 → $17 | $4.60 | +269.97% | 2 | May 16, 2025 | |
| JBIO Jade Biosciences | Reiterates: Outperform | $17 | $8.29 | +105.07% | 2 | May 15, 2025 | |
| ANRO Alto Neuroscience | Reiterates: Neutral | $4 | $2.23 | +79.37% | 4 | May 15, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $32 → $30 | $14.00 | +114.36% | 8 | May 7, 2025 | |
| VERA Vera Therapeutics | Maintains: Neutral | $34 → $26 | $21.15 | +22.93% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $28 | $43.43 | -35.53% | 7 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $43 | $14.50 | +196.55% | 10 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $43 | $18.26 | +135.49% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $0.30 | +892.06% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $17.29 | +108.21% | 6 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $28 | $5.71 | +390.37% | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $17.76 | +63.33% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6 | $9.12 | -34.21% | 9 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $147 | $124.91 | +17.69% | 9 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 → $48 | $36.66 | +30.93% | 12 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $12 | $1.40 | +760.22% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $2.70 | +714.81% | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $49 | $31.69 | +54.62% | 8 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $3.12 | +124.36% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $3.55 | +209.86% | 13 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $14.89 | +182.16% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $17 | $11.67 | +45.74% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.34 | +3,177.71% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $3.70 | +35.14% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $55.00 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $2.56 | +95.69% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $14.56 | +919.92% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $8.30 | +8,574.70% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $21.87 | +1,180.29% | 1 | Apr 21, 2017 |
Biogen
Jun 12, 2025
Reiterates: Neutral
Price Target: $121
Current: $126.56
Upside: -4.39%
Pharvaris
Jun 5, 2025
Reiterates: Outperform
Price Target: $27
Current: $16.56
Upside: +63.04%
Vigil Neuroscience
May 22, 2025
Downgrades: Neutral
Price Target: $13 → $8
Current: $7.88
Upside: +1.52%
Travere Therapeutics
May 16, 2025
Reiterates: Outperform
Price Target: $30
Current: $14.10
Upside: +112.77%
Gossamer Bio
May 16, 2025
Reiterates: Outperform
Price Target: $4
Current: $1.24
Upside: +222.58%
Solid Biosciences
May 16, 2025
Maintains: Outperform
Price Target: $18 → $17
Current: $4.60
Upside: +269.97%
Jade Biosciences
May 15, 2025
Reiterates: Outperform
Price Target: $17
Current: $8.29
Upside: +105.07%
Alto Neuroscience
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $2.23
Upside: +79.37%
Denali Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $14.00
Upside: +114.36%
Vera Therapeutics
May 7, 2025
Maintains: Neutral
Price Target: $34 → $26
Current: $21.15
Upside: +22.93%
May 5, 2025
Maintains: Underperform
Price Target: $26 → $28
Current: $43.43
Upside: -35.53%
Apr 21, 2025
Maintains: Outperform
Price Target: $43
Current: $14.50
Upside: +196.55%
Mar 14, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $18.26
Upside: +135.49%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $0.30
Upside: +892.06%
Mar 12, 2025
Reiterates: Outperform
Price Target: $36
Current: $17.29
Upside: +108.21%
Mar 12, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $5.71
Upside: +390.37%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $17.76
Upside: +63.33%
Feb 12, 2025
Reiterates: Neutral
Price Target: $6
Current: $9.12
Upside: -34.21%
Feb 7, 2025
Maintains: Outperform
Price Target: $157 → $147
Current: $124.91
Upside: +17.69%
Jan 13, 2025
Reiterates: Neutral
Price Target: $46 → $48
Current: $36.66
Upside: +30.93%
Nov 8, 2024
Maintains: Outperform
Price Target: $19 → $12
Current: $1.40
Upside: +760.22%
Oct 3, 2024
Initiates: Outperform
Price Target: $22
Current: $2.70
Upside: +714.81%
Aug 9, 2024
Maintains: Outperform
Price Target: $50 → $49
Current: $31.69
Upside: +54.62%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $3.12
Upside: +124.36%
Aug 2, 2024
Reiterates: Outperform
Price Target: $11
Current: $3.55
Upside: +209.86%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $14.89
Upside: +182.16%
Jul 11, 2024
Reiterates: Outperform
Price Target: $17
Current: $11.67
Upside: +45.74%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.34
Upside: +3,177.71%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $3.70
Upside: +35.14%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $55.00
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $2.56
Upside: +95.69%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $14.56
Upside: +919.92%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $8.30
Upside: +8,574.70%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $21.87
Upside: +1,180.29%